Cabio Biotech (Wuhan) Co., Ltd. Stock: price and insider trades · China
嘉必优
No insider purchase over the last 90 days. The latest, by 耿安锋, was filed 30 Jan 2024.
Cabio Biotech (Wuhan) Co., Ltd.: what insiders have been doing
Cabio Biotech (Wuhan) Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). No insider at Cabio Biotech (Wuhan) Co., Ltd. has published a filing in the past twelve months. The most recent one dates from 29 August 2025.
The full history, which starts in 2022, counts 10 purchases against 8 sales.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +50.4%Entry CN¥13.10 · Close at T+365 CN¥19.70
- +31.6%Entry CN¥14.70 · Close at T+365 CN¥19.35
- +21.2%Entry CN¥15.97 · Close at T+365 CN¥19.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 20,000 shares100.0% of flowA股XSHGSSE:173000009480907740
- 10,736 shares24.7% of flowA股XSHGSSE:173000007293204160Canonical exit: 29 Apr 2024 (T+90)
- 7,000 shares24.0% of flowA股XSHGSSE:173000007270051700Canonical exit: 18 Apr 2024 (T+90)
- 5,000 shares8.9% of flowA股XSHGSSE:173000007264332960Canonical exit: 17 Apr 2024 (T+90)
- 3,000 shares1.6% of flowA股XSHGSSE:173000007258690750Canonical exit: 15 Apr 2024 (T+90)
- 1,000 shares0.7% of flowA股XSHGSSE:173000007164666620Canonical exit: 11 Mar 2024 (T+90)
- 3,000 shares1.8% of flowA股XSHGSSE:173000007146552500Canonical exit: 3 Mar 2024 (T+90)
- 10,000 shares100.0% of flowA股XSHGSSE:173000007123030080Canonical exit: 22 Feb 2024 (T+90)
- 1,000 shares0.7% of flowA股XSHGSSE:173000007065879840Canonical exit: 31 Jan 2024 (T+90)
- 8,000 shares75.3% of flowA股XSHGSSE:173000006286345380
- 10,800 shares66.1% of flowA股XSHGSSE:173000006217658800
- 47,900 shares98.6% of flowA股XSHGSSE:173000006217658880
- 4,100 shares25.0% of flowA股XSHGSSE:173000006214180770
- 60,000 shares96.6% of flowA股XSHGSSE:173000006064034430
- 400 shares7.4% of flowA股XSHGSSE:173000005490637820Canonical exit: 26 Jul 2022 (T+90)
- 200 shares3.8% of flowA股XSHGSSE:173000005476061200Canonical exit: 25 Jul 2022 (T+90)
- 5,000 shares76.0% of flowA股XSHGSSE:173000005229341340
- 2,000 shares88.8% of flowA股XSHGSSE:173000005206404200
18 of 18 declarations
About Cabio Biotech (Wuhan) Co., Ltd.
嘉必优 is a healthcare and pharmaceutical company listed on the Shanghai Stock Exchange. It specializes in the development and marketing of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
